The Effect of AC-134 in Chronic Kidney Diseases

Launched by TAICHUNG VETERANS GENERAL HOSPITAL · May 28, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment called AC-134 to see how it affects people with chronic kidney disease (CKD). The researchers want to find out if adding AC-134 can help improve kidney function, reduce protein in the urine, and lower levels of harmful substances that build up when the kidneys aren't working well. The trial is not yet recruiting participants, but it aims to include adults aged 20 to 90 who have stage 3 to 5 CKD, as long as they are not on dialysis.

To participate, individuals must sign a consent form and meet certain criteria. They should not be using other charcoal supplements, and there are some health conditions that could prevent someone from joining, such as recent kidney injury, severe heart or liver diseases, or active infections. If eligible, participants will have the opportunity to help researchers learn more about a potential new way to treat chronic kidney disease, which could lead to better health outcomes for many people.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 20-90 years.
• • Diagnosed with stage 3-5 chronic kidney disease, excluding dialysis patients.
• • Signed informed consent is required before enrollment.
• Exclusion Criteria:
• • Use of other brand-activated charcoal supplements during the study period.
• • Pregnant or lactating women.
• • Patients who have undergone kidney transplantation.
• • Obstructive nephropathy within the past month.
• • Acute kidney injury within the past three months.
• • Gastrointestinal bleeding or severe constipation within the past three months.
• • Patients with active malignancy within the past two years.
• • Severe cardiovascular diseases such as congestive heart failure New York class III-IV or cerebrovascular disease
• • Severe liver disease, such as liver cirrhosis with ascites.
• • Active infectious disease